Sex: F
Vaccine: COVID19, UNK
Symptoms: Rheumatoid arthritis, Skin exfoliation
Clinical narrative: Rheumatoid arthritis flares on hand, fingers, elbow and lower right arm; Scaling on elbow and right lower arm; This is a solicited report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4379113-00 (AbbVie).  A 73-year-old female patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) intramuscular for covid-19 immunisation; adalimumab (HUMIRA), (ongoing) (Lot number: 1159929) at unk (citrate free), subcutaneous for rheumatoid arthritis. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: RHEUMATOID ARTHRITIS (medically significant), outcome "not recovered", described as "Rheumatoid arthritis flares on hand, fingers, elbow and lower right arm"; SKIN EXFOLIATION (non-serious), outcome "unknown", described as "Scaling on elbow and right lower arm". The action taken for adalimumab was unknown.  The reporter's assessment of the causal relationship of "rheumatoid arthritis flares on hand, fingers, elbow and lower right arm" and "scaling on elbow and right lower arm" with the suspect product(s) BNT162b2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment.  Causality for HUMIRA (ADALIMUMAB): The reporter's causality for the event(s) of rheumatoid arthritis flare on hand, Fingers, Elbow and lower right arm with Humira (ADALIMUMAB) was a reasonable possibility. The reporter's causality for the event of scaling on elbow and right lower arm was not provided.   The reporter's assessment of the causal relationship of the events Rheumatoid arthritis flare up and Localized exfoliation with the suspect product BNT162B2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment.  Clinical information: Solicited report by a consumer of an elderly female with events of non-Serious Rheumatoid arthritis flare up on hand, Fingers, elbow and lower right arm and scaling on elbow and right lower arm with Humira (ADALIMUMAB). There was no reported medical history. On an unknown date, the patient experienced rheumatoid arthritis flare up on hand, Fingers, Elbow and lower right arm and scaling on elbow and right lower arm. Pfizer BioNTech covid 19 vaccine (Tozinameran) was also considered suspect. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on possible temporal association the causal role of BNT162B2 Vaccine cannot be excluded for reported events .Case will be reviewed further on receipt of FU information  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate